drugset
drugset / Trial / NCT01367613

Open-Label Treatment Extension of Protocol MNTX 302

NCT01367613 ↗

Phase 3 Completed 89 enrolled Bausch Health Americas, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a 3 month open-label extension study that allows patients who completed Protocol MNTX 302 to receive SC MNTX.

Timeline

Start
2004-03
Primary completion
2006-01
Completion
2006-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylnaltrexone Other / unclassified — Subcutaneous

Indications

No indication recorded.